FDA Clearance Tracker · P950037-S280
Solia CSP S 53; Solia CSP S 60
Last checked: Nov 20, 2026Latest source record: Feb 12, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Feb 12, 2026
Approved
Time to decision
114 days
Received Oct 21, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P950037-S280
- Device name
- Solia CSP S 53; Solia CSP S 60
- Applicant
- Biotronik, Inc.
- Applicant location
- Lake Oswego, OR
- Received
- Oct 21, 2025
- Decided
- Feb 12, 2026
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P950037
Device type
- Device type
- Drug eluting permanent right ventricular (RV) or right atrial (RA) pacemaker electrodes (NVN)
- Device class
- Class III
- Specialty
- CardiologyElectrophysiology
FDA's approval statement
As written in FDA's record.
Approval for the Solia CSP S pacing leads intended for implantation in the left bundle branch area.
Source documents
Other decisions for Biotronik, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- BIOMONITOR IV (471155)510(k)
K261074 · Decided May 1, 2026 · 30 days after receipt
Device type: Recorder, Event, Implantable Cardiac, (With Arrhythmia Detection) (MXD) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.